A Novel Therapeutic for the Treatment and Prevention of Hearing Loss from Acoustic Trauma

Abstract

During this granting period we have demonstrated that our therapeutic peptide, P13/T1, was efficacious in treating permanent and severe noise-induced hearing loss. Using a steady-state model of noise exposure (117 db for 2 hours), T1/P13 was administered one hour after noise using a variety of doses and routes of administration. Both topical (ear drop) and subcutaneous (SQ) routes of administration of T1/P13 resulted in a reduction in hearing loss seen after noise insult, with the most dramatic improvement seen after SQ administration. P13/T1 also demonstrated an improvement in hearing thresholds when given either one or 24 hours before the noise insult. Mass spectrometry studies demonstrated that P13/T1 reaches the inner ear when given either subcutaneously or topically. Gene expression studies show that P13/T1 impacts numerous genes related to noise-induced hearing loss.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2016
Accession Number
AD1035025

Entities

People

  • Sharon Mccoy
  • Steven Hefeneider

Tags

DTIC Thesaurus Topics

  • Ear
  • Gene Expression
  • Health Services
  • Hearing Disorders
  • Hearing Loss
  • Impulse Noise
  • Mass Spectrometry
  • Medical Personnel
  • Organ Of Corti
  • Rodents
  • Spectrometry
  • Steady State

Readers

  • Acoustics.
  • Mathematics or Statistics
  • Trauma Surgery or Emergency Medicine.